Alcon acquires ophthalmic division

Article

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

SMI, a private company based in Germany, deals with ocular guidance technology such as real-time eye tracking, automatic registration of ocular imaging and IOL positing and alignment guidance.

Alcon will integrate SMI into its existing global cataract portfolio and will further develop existing products that improve patient outcomes in cataract surgery. This includes the IOL used to treat cataracts and correct refractive errors such as astigmatism and presbyopia.

Sabri Markabi, Senior Vice President of Research and Development at Alcon, commented, "This acquisition further strengthens Alcon's position in the cataract surgery market with an expansion into leading ocular tracking technology. The stare-of-the-art guidance technology provides surgeons with customization options and automated solutions, enabling optimal outcomes for their cataract patients including underlying refractive conditions."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.